Napo Announces Successful Clinical Results In Phase 2 Study Of Crofelemer In Acute Adult Infectious Diarrhea

Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU) is pleased to announce the positive results of a successfully completed Phase 2 trial for CRO-ID (crofelemer for the treatment of acute adult infectious diarrhea) conducted by its partner, Glenmark Pharmaceuticals Limited (BSE: Glenmark).

More: continued here

Filed under: GastroIntestinal / Gastroentorology on April 11th, 2008